New Data Support Long-Term Use Of AMBIEN CRTM (zolpidem Tartrate Extended- Release) Tablets C(IV) For Up To 24 Weeks
Fri, 14 Jul 2006 06:00 AM EST
... Sanofi-aventis(Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) today announcedresults from a study that demonstrated AMBIEN CR is well-tolerated andeffective in improving sleep onset and maintenance for up to six months inpatients with chronic primary insomnia when taken as needed for up to sevennights per week, without rebound insomnia following discontinuation. [click link for full article] ...
Related Topics
- Zolpidem
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Long Term Care
- Data & Statistics
- Loratadine and Pseudoephedrine
- Data Analysis
- Acute Care
- Isosorbide Dinitrate, Tablets or Extended-Release Tablets or Capsules
- National Data
- Niacin Extended Release
- Lovastatin Extended Release
- Isradipine Extended-Release Tablets
- Valproic Acid Delayed or Extended-Release or Sprinkle Capsule
- Long Term Care/ltc
- Metformin Extended-Release
- Pseudoephedrine Extended Release
- Vegetative state (long-term coma)
- Chronic (long-term) kidney failure
- Long-term incontinence or urinary retention
- Complications due to long-term catheter use

Not Signed In -
